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ABSTRACT

Human islet amyloid polypeptide (IAPP, a.k.a. amylin) is a 37-residue peptide
hormone co-synthesized and co-secreted with insulin by pancreatic β-cells for glycemic
control. Extensive research indicates that the amyloid aggregation of IAPP into cross-β
amyloid fibrils is a ubiquitous phenomenon as well as a major factor in the development
and pathogenesis of type 2 diabetes mellitus (T2D), which is a long-term metabolic
disorder compromises the quality of life of millions globally. The amyloid IAPP
aggregation products, either soluble intermediate oligomers or mature fibrils, are found
toxic to human cells and capable of eliciting systemic damage in T2D patients. Recent
studies reveal that IAPP is able to cross the blood-brain barrier and co-aggregate with
human amyloid-beta (Aβ), which is the protein associated with another amyloid
neurodegenerative disorder, the Alzheimer’s disease (AD). In vitro experiments
demonstrate that soluble IAPP could significantly accelerate the aggregation of Aβ, with
accumulating clinical and epidemiological evidences also suggest that T2D and AD are
linked together. Despite the significant differences in their pathologies, T2D is suggested
as a risk factor for AD. Here, we investigate the possible mechanism of the co-aggregation
of IAPP and Aβ to explore the cross-talk between these two diseases and propose that IAPP
promotes Aβ aggregation by reducing the aggregation free energy barrier through its
binding with Aβ. In addition, with the fact that IAPPs are stored inside β-cell granules
without apparent aggregation in healthy individuals, we also study the physiological
environment inside β-cell granules and its endogenous inhibition effect on IAPP
aggregation. Our work demonstrates that Zn2+ coordinated molecular complex might be
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important to stabilize IAPP and hence the endogenous inhibition. Moreover, we study the
interactions between IAPP and two different materials, the small molecule epigallocatechin
gallate (EGCG) and the star-shaped polymer poly(2-hydroxyethyl acrylate) (PHEA). Our
study demonstrates both EGCG and PHEA as inhibitors against amyloidogenesis, while
perform in different strategies. EGCG is able to inhibit IAPP aggregation and result in
minimizing the population of toxic oligomers and protofibrils, while PHEA accelerates
IAPP fibrillation to circumvent accumulation of the more toxic intermediates.
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CHAPTER ONE
IAPP and Amyloid Aggregation

Function of IAPP
Human islet amyloid polypeptide (IAPP, a.k.a. amylin) is a 37-residue peptide
hormone co-synthesized, co-stored, and co-secreted with insulin by pancreatic β-cells for
glycemic control.1,2 IAPP is synthesized from a 67-residue precursor protein, proIAPP.
Through proteolysis and posttranslational modification processes, including peptide
cleavage, C-terminal amidation, and finally a disulfide bond formation between residues 2
and 7, the transformation from proIAPP to the biologically active IAPP is complete, with
the sequence as KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY.3,4 IAPP is
known as a synergistic partner to insulin in terms of its function, which is able to control
the blood glucose level by slowing down gastric emptying, inhibiting digestive secretion,
and promoting satiety.5,6Addiitonally, IAPP is also reported to contribute to the bone
metabolism, along with the related peptides calcitonin and calcitonin gene-related
peptides.7

IAPP Aggregation and Type 2 Diabetes
IAPP is characterized as a peptide of high propensity to aggregate and readily to
form amyloid fibrils in vitro at μM concentration within hours.8 Accumulating studies
report the observation of IAPP enriched amyloid plaques in the pancreas of type 2 diabetes
(T2D) patients, as well as the quick formation of amyloid fibrils in vitro. As with many
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other amyloid proteins, the amyloid aggregation of IAPP is a nucleation-dependent process
with an “all-or-none” sigmoidal kinetics, where an initial lag phase of nucleation is
followed by rapid elongation and saturation. 9–11 Both the aggregation intermediates and the
mature amyloid fibrils of IAPP are found toxic to human cells, with the intermediates
identified as the more toxic species. Previous study has shown that IAPP1-19 is a non-fibril
forming segment, while its toxicity is similar to that of the full-length peptide.12 Study of
IAPP oligomers also find them could disrupt cell coupling, induce apoptosis, and impair
insulin secretion in isolated human islets. 13 Together with other studies, the toxic oligomer
hypothesis is proposed, claiming that it is the intermediate oligomers instead of the amyloid
fibrils are the most toxic species and may be responsible for the β-cell death in T2D.14,15

Co-aggregation of IAPP and Aβ
Alzheimer’s disease (AD) is another common aging-associated disease similar to
T2D, with the shared pathological hallmarks such as peptide amyloid aggregation and
deposition of amyloids. The aberrant aggregation of human amyloid-β (Aβ) and IAPP is
implicated in AD and T2D respectively, with both peptides can self-assemble into amyloid
fibrils and accumulate in human tissues as amyloid deposits. 16–22 Accumulating clinical
and epidemiological research suggest that T2D and AD are linked to each other. Studies
report a relatively frequent appearance of mixed pathologies of both diseases, and T2D has
also been found as a major risk factor for AD. 23–33 Given experimental evidence of IAPP
being able to cross the blood-brain barrier and possibly expressed in sensory neurons, the
co-aggregation of IAPP and Aβ has been explored to uncover the cross-talk between T2D
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and AD.34–36 Both IAPP and Aβ can form amyloid fibrils with similar characteristic of the
cross-β structure, but their aggregation rates are quite distinct. In vitro experiments under
same concentration conditions reveal IAPP aggregates much faster than Aβ, while their
mixture at 1:1 ratio aggregates with a much shorter lag phase than Aβ alone but slightly
longer than IAPP.37,38 These studies also report the mixture aggregates in a similar manner
as IAPP or Aβ self-aggregation (e.g., in terms of aggregation kinetics, fibril morphology,
and the ability to disrupt membranes), and eventually forms IAPP/Aβ hetero-complexes
and hetero-fibrils. Based on these observations, it has been postulated that IAPP and Aβ
would form hetero-complexes first upon mixture, and the complexes subsequently
aggregate.

The Endogenous Inhibition of IAPP Aggregation
IAPP is known as highly aggregation prone, however this peptide is stored inside
β-cell granules at mM concentration for hours without apparent aggregation in healthy
individuals before its secretion to the bloodstream. 39 Therefore, the physiological
environment inside β-cell granules endogenously inhibits the IAPP aggregation.
Islet β-cell granules have a pH value of 5.5, which is below the physiological pH
of 7.4. The inhibition of IAPP aggregation by low pH has been studied in vitro, with the
observations of increased aggregation lag time and decreased fibrillization rate compared
to that under the physiological pH condition.40,41 Previous studies suggest the protonated
histindine18 (H18) of IAPP at low pH would introduce electrostatic repulsion between
IAPPs and result in inhibition effct. 42,43 As the pH value inside β-cell granules is close to
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the isoelectric point of H18, it may contribute to the endogenously inhibition, but not likely
to be the key factor since a significant portion of IAPPs are still unprotonated.40,44
In addition to IAPP, β-cell granules also feature the high concentration of Zn2+ and
other molecules including insulin and C-peptide. The large amount of Zn2+ inside granules
is maintained by a β-cell-specific zinc transporter – ZnT8, and is believed important for
the efficient storage of insulin: Zn2+ coordinates the formation of insulin hexamers, which
constitute insulin crystals as the dense core of β-cell granules.45,46 Zn2+ has been explored
having a concentration-dependent effect on IAPP aggregation. A low concentration of Zn2+
could cross-link IAPP oligomers and therefore promotes the aggregation, while higher ion
concentration leads to an inhibition effect due to the formation of Zn2+-IAPP complex via
coordination with H18 and hence the electrostatic repulsion among complexes.47–50 With
the concentration of Zn2+ kept increasing, the induced screening effect would reduce
electrostatic repulsion and the aggregation would be slightly promoted again. 49,50
Several studies reveal insulin has a strong inhibition effect on IAPP aggregation.51–
54

However, since most insulin are found as the insoluble crystal-like dense core inside β-

cell granules while IAPPs are exclusively found in the soluble halo fraction, their
contribution to the endogenously inhibition may be limited. C-peptide is another peptide
co-localized with Zn2+ and IAPP, which is a proteolytic product of proinsulin and able to
bind multiple IAPP and promote aggregation. 48 Upon mixture with Zn2+, C-peptide binds
Zn2+ with a 1:1 ratio in stoichiometry and adopts specific structures with reduced charges,
which might bind and stabilize IAPP afterwards.55 It has been hypothesized that a balance
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of Zn2+ and C-peptide appears important for maintaining the native state of IAPP in
addition to the low pH effect.

Strategies for Mitigating IAPP-associated Toxicity
Aggregation inhibition with the use of peptides, small molecules as well as
polymeric nanoparticles (NPs) have been long explored to develop possible strategies
against amyloid-mediated toxicity. Among all the approaches, the small molecule
epigallocatechin gallate (EGCG, a.k.a. epigallocatechin-3-gallate) is a polyphenol small
molecule and possesses the advantages of naturally occurring, non-toxic at moderate
concentration, and modest water solubility (33.3-100 g/L). Previous studies reveal that
upon interfacing with EGCG, the IAPP aggregation is rendered off-pathway and the mature
IAPP fibrils even display remodeled.56–58 A possible mechanism is that EGCG binds IAPP
with aromatic residues, and therefore traps IAPP into an early intermediate state prior to
IAPP amyloid formation with reduced toxicity. Differently, the star-shaped polymer
poly(2-hydroxyethyl acrylate) (PHEA) nanostructure shows mitigating IAPP-associated
toxicity by promoting aggregation. The PHEA stars are weakly negatively charged and
contains multiple rigid arms, with each arm serves as linear scaffold for IAPP binding and
promotes IAPP aggregation. Binding between IAPP and PHEA star induce a unique
“stelliform amyloid” morphology, which displays reduced toxicity both in vitro and ex vivo.
As a result, PHEA circumvents the accumulation of toxic intermediates and mitigates
IAPP-associated toxicity.
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CHAPTER TWO
IAPP Promotes Aβ Aggregation by Binding-induced Helix-unfolding of the
Amyloidogenic Core

Introduction
Previous studies reveal the co-aggregation of IAPP and Aβ, and observe the heterocomplex/hetero-fibril formation. Upon the formation of hetero-complexes, conformational
changes have been detected, but the molecular details and mechanisms of co-aggregation
remain unknown. Both segment Aβ40 and Aβ42 are implicated in the pathogenesis of AD,
with Aβ42 is characterized as more hydrophobic, more cytotoxic, and the most
amyloidogenic form of this peptide. Here, by combining atomistic discrete molecular
dynamics (DMD) simulations with complementary thioflavin-T fluorescence assay (ThT),
we study the interactions between IAPP and Aβ42, the formation of hetero-complexes, and
also the corresponding structures and conformational dynamics upon binding in order to
understand the co-aggregation behaviors. Through our work, we first identify the IAPPAβ heterodimer as the most populated hetero-complexes during the early stage of coaggregation when IAPP and Aβ are mixed at equimolar ratio in silico. The residue-wise
inter-peptide interactions revealed by DMD simulations are consistent with experimentally
identified hot-spot regions for IAPP-Aβ binding.59 Our simulation results also suggest the
helix unfolding of Aβ amyloidogenic region (16KLVFFAE22) as the major conformational
change upon the formation of heterodimer. The complementary ThT assay applied by our
collaborators confirms the accelerated amyloid aggregation of IAPP/Aβ mixture compared
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to Aβ. Using an approach proposed by the Wetzel group, further analysis about the
aggregation kinetics suggests that the rate-limiting step of Aβ42 aggregation is
conformational changes taking place in approximately two peptides. 10 Together with our
computational results and previous reports of Aβ42 oligomerization, we propose an
aggregation mechanism that the helix unfolding of Aβ16-22 corresponds to the major free
energy barrier of Aβ42 aggregation, which can take place in various Aβ42 oligomers
populated during the early stage of aggregation. 60,61 Upon mixing with IAPP, the formation
of IAPP-Aβ heterodimer induces the helix unfolding of Aβ16-22, which subsequently
reduces the aggregation free energy barrier and accelerates the co-aggregation compared
to Aβ42 alone. Our works offer a potential molecular mechanism for the increased AD risk
in T2D patients as observed in clinical and epidemiological studies.

Results and Discussion
Heterodimer formation is the first step towards the co-aggregation of IAPP and Aβ. We
perform all-atom DMD simulations of multiple IAPP and Aβ at 1:1 ratio to investigate the
assembly dynamics of the peptide mixture. Two sets of molecular systems are studied, with
one contains two IAPPs along with two Aβs and another has four peptides of each species,
where the same peptide concentration is maintained. We perform 50 independent
simulations with each lasted 200ns for the smaller system and 20 independent simulations
with each lasted 100ns for the larger system at 300K, simulations are started with different
initial inter-molecular distances and orientations.
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To capture the assembly dynamics, we calculate the number of atomic contacts
between various peptides and also monitor the formation of peptide clusters. When two
IAPPs and two Aβs are mixed, the total number of contacts is dominated by the crossspecies interactions, while both the contacts among IAPPs and among Aβs are significantly
smaller (Fig. 2-1). The number of IAPP-Aβ contacts increases rapidly in the early stage of
simulations with obvious lag-time observed for both IAPP-IAPP and Aβ-Aβ interactions,
suggesting an initial hetero-complexes formation in the mixture. For the peptide clustering
analysis, we compute the time evolution of various cluster species weighted by the number
of peptides in a cluster (Fig. 2-2A). We observe rapid formation of IAPP-Aβ heterodimer
following a decrease of initial monomers. The heterodimer is the most populated species
before they finally associate into the hetero-hexamer. Similar association dynamics can
also be observed for the larger system, where the heterodimer is also the most populated
species during early assembly process, although other higher order oligomers (such as two
IAPPs bound to one or three Aβs) are later observed before the appearance of heterooctamer (Fig. 2-2B).
Hence, our simulations suggest that when IAPP and Aβ peptides are mixed at an
equimolar ratio, the cross-species interaction dominates over their self-associations during
the early assembly. The rapid formation of hetero-complexes could be explained by the
opposite net charges of the two peptides (i.e., the net charges of IAPP and Aβ are +2e and
-3e, respectively) and the relatively long-range electrostatic interactions under the
physiological condition (the Debye length is ~10Å). Our results also indicate that the
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heterodimer of IAPP and Aβ is the major intermediate species populated towards their coaggregation.

Computationally observed inter-peptide interactions for both cross- and self-association
of IAPP and Aβ are consistent with previous experiments. The hot-spot regions for both
cross- and self-association of IAPP and Aβ have been investigated experimentally.59 For
experimental validation of our simulations, we perform DMD simulations of one IAPP
with one Aβ mixture (i.e., cross-association), along with control simulations of two IAPPs
and two Aβs respectively (i.e., self-association). We carry out 20 independent simulations
at 300K with each lasted 600ns for each molecular system, and the last 300ns trajectories
are used to compute the residue-wise binding frequency maps (Fig. 2-3). From simulations
of IAPP-Aβ cross-association, we identify several "hot regions" with high binding
frequencies, including residues 8-18 and 22-28 in IAPP, as well as residues 17-24 and 2742 in Aβ, (Fig. 2-3A). Same regions are also important for the self-associations of IAPP
and Aβ (Fig. 2-3B&C). Besides, shared features can be observed between cross- and selfassociations. For instance, an "anti-parallel" binding pattern (i.e., perpendicular to the
diagonal) due to interactions between C-terminal residues of Aβ is present in both IAPPAβ and Aβ-Aβ contact frequency maps (Fig. 2-3A&B). Similar patterns formed by the hotspot residues of IAPP (e.g., 8-18 and 22-28) could also be found in both IAPP-Aβ and
IAPP-IAPP maps (Fig. 2-3A&C). Our observations agree very well with previous
experimental reports, in which the hot regions for cross- and self-associations are
determined as residues 8-18, 22-28 in IAPP, and residues 19-22, 27-32, 35-40 in Aβ.59
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These similarities suggest a common binding mechanism in cross- and self-associations of
IAPP and Aβ, which may arise from their similarity in sequences. 62–64 Both IAPP and Aβ
are amyloidogenic with about 50% similarity in sequences, and the sequences with the
highest degree of similarity are 10-16, 21-27 in IAPP and 15-21, 26-32 in Aβ (Fig. 2-3D),
all of which are within or close to the hot regions determined both experimentally and
computationally. Therefore, the regions important for both IAPP and Aβ self-associations
also mediate their cross-association, and their cross- and self-associations could occur in a
competitive manner.

Conformational changes of IAPP and Aβ heterodimer upon cross-association. We further
study the structural properties of IAPP-Aβ heterodimer. For comparison, we also perform
simulations of IAPP and Aβ monomers and dimers, following the same protocol - i.e., 20
independent simulations of 600ns at 300K, with trajectories of the last 300ns are used to
compute the secondary structure propensities (Fig. 2-4 and Fig. 2-5). For the Aβ monomer,
the amyloidogenic region (Aβ16-22) is partially helical, while the N- and C-termini mostly
adopt β-sheet conformation (Fig. 2-4A&B). IAPP monomer contains a stable helix in the
N-terminus, with the amyloidogenic IAPP22-29 mostly unstructured with a weak helical
propensity (Fig. 2-4C&D and Fig. 2-5C&D). Compared to monomers, both IAPP and Aβ
homodimers show an overall increase of α-helix (Fig. 2-4A&C), consistent with many
experimental observations of the increased α-helical contents during early stage of amyloid
aggregation of IAPP and Aβ before the final conversion to β-rich fibrils.65,66 In contrast,
the heterodimer has the β-sheet propensity increased while helix propensity decreased for
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both peptides compared to their monomers, especially in the corresponding amyloidogenic
regions (e.g., IAPP22-29 and Aβ16-22 in Fig. 2-4). Given the importance of these
amyloidogenic regions in forming the cross-β architecture in the mature amyloid fibrils,
the conformational transition form α-helix to β-sheet in these regions makes the peptides
more aggregation prone upon their cross-association.67

Helix unfolding of Aβ16-22 is the major conformational change upon binding with IAPP
in the heterodimer. To better understand the conformational dynamics of IAPP and Aβ
upon association as the heterodimer, we further analyze the simulation trajectories of the
monomers and the heterodimer by focusing on their corresponding amyloidogenic regions.
Following a similar approach in protein folding studies, we monitor the folding and
unfolding of helixes in the amyloidogenic regions - i.e., IAPP22-29 and Aβ16-22.68,69
During simulations of Aβ monomer, we could observe the dynamics of helix unfolding and
refolding of the amyloidogenic Aβ16-22 (e.g., 22 unfolding and 9 refolding events), where
the population of the helical state was approximately 61% (Fig. 2-6). In the presence of
IAPP, the number of helix refolding events is drastically reduced (e.g., 18 unfolding and
only 1 refolding events) and the population of the helical state is reduced to ~57%. In terms
of IAPP22-29, the helix population is slightly changed from ~21% in monomer to ~20%
in heterodimer, and the helix unfolding/refolding dynamics in heterodimer is slower but
still frequent (i.e., from 72/56 to 34/18). These observations indicate that the binding
between IAPP and Aβ in the heterodimer increases the free energy barriers of helix
unfolding/refolding of their corresponding amyloidogenic regions. For IAPP22-29, the
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barrier increase doesn’t change the equilibrium between helical and non-helical
conformations, and the frequent unfolding/refolding dynamics suggests that our
computational observations are significant. The conformation dynamics of Aβ16-22, on
the other hand, is shifted towards the non-helical state upon binding with IAPP. With the
rare observation of helix refolding events of Aβ16-22 suggesting a slow conformational
dynamics, the conformational equilibrium might not have been reached in our constant
temperature simulations (e.g., up to 600ns in each independent simulation).
In order to better sample the conformational equilibrium of the heterodimer, we
apply replica exchange DMD (REXDMD) simulations, where parallel simulations at
different temperatures are performed with Monte-Carlo based periodic exchanges between
replicas of neighboring temperatures. 70 Although the interpretation of kinetics might be
challenging compared to serial ones at constant temperatures, replica exchange simulations
have been widely applied for enhanced sampling of thermodynamic equilibrium by
overcoming energy barriers at high temperatures. We perform REXDMD simulations for
IAPP monomer, Aβ monomer, and the heterodimer, with each replica of simulations lasted
200ns and trajectories of the last 150ns are used in data analysis. Using the weighted
histogram analysis method (WHAM), we compute the specific heat (Cv) as the function of
temperature (Fig. 2-7A).71 A peak in the Cv plot usually corresponds to conformational
transitions around the temperature with the heights indicating the transition cooperativity.
To uncover the details of conformational transitions, we also compute the temperature
dependence of the number of inter-peptide contacts in the heterodimer (Fig. 2-7B) and
secondary structure contents of both Aβ and IAPP in monomers and heterodimer
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simulations (Fig. 2-7C&D). The weak Cv peak of IAPP around ~305K corresponds to the
gradual and non-cooperative unfolding of helixes (Fig. 2-7A&D), while the peak of Aβ at
a higher temperature (~325K) results from unfolding of both helices and strands (Fig. 27A&C). Remarkably, the heterodimer displays a high Cv peak around ~322K mainly due
to the dissociation of a large number of inter-peptide contacts (Fig. 2-7B). Compared to the
monomers, the strong inter-peptide binding in the heterodimer significantly reduces the
helical content of Aβ (mainly in the amyloidogenic region of Aβ16-22) and increases its
β-sheet content (Fig. 2-7C). For IAPP, Aβ binding does not significantly change the
conformational dynamics with only a slight increase of the β-sheet content (Fig. 2-7D).
Therefore, our REXDMD simulations confirms the IAPP-binding induced helix unfolding
of Aβ16-22 as observed in constant temperature simulations (Fig. 2-4 and Fig. 2-6).
To better characterize the conformational change of Aβ16-22 upon IAPP binding,
we further compute the potential mean force (PMF, i.e., the effective free energy
landscapes) of the fragment with respect to the number of residues in helical content and
the end-to-end distance at 300K based on our REXDMD simulation results (Fig. 2-8). For
both monomer and heterodimer, four major basins could be observed, corresponding to
helical, partially helical and non-helical states with either compact or extended
conformations (e.g., typical snapshot structures in Fig. 2-8). The partially unfolded state
corresponds to the intermediate of helix unfolding and the saddles connecting basins denote
the folding pathways. Compared to Aβ16-22 in the monomer, the binding with IAPP
renders the non-helical basins deeper, the helical and partially helical states shallower, and
the saddle between the non-helical and the intermediate states broadened. Therefore, our
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results suggest that binding with IAPP in the heterodimer at 300K shifts the conformational
equilibrium of Aβ16-22 from helix towards extended non-helical conformational states,
readily to form β-sheets (e.g., the snapshots in Fig. 2-8).

In vitro studies of IAPP and Aβ self- and cross-aggregation. We apply the ThT
fluorescence assay to study the self- and cross-aggregation of IAPP and Aβ. Mixtures of
IAPP and Aβ42 at equimolar ratio with different concentrations are tested (1.0, 2.0, 2.5,
3.0, 3.5, 4.0, and 5.0μM accordingly) and compared with control groups of individual
peptides aggregating at the same concentrations. Multiple repeats are done for each
molecular system at a given concentration. Sigmoidal aggregation kinetics has been
observed in all peptide systems (e.g., Fig. 2-9), and the corresponding lag time and fibril
elongation rate are obtained by fitting the data with an empirical sigmoidal function (Fig.
2-10A&B). Our results are consistent with previous experimental reports that IAPP is more
aggregation prone than Aβ with shorter lag phases for all the tested concentrations. 30,72 The
lag time of the mixture is comparable to that of the IAPP alone and significantly reduced
compared to Aβ alone, consistent with previous report that mixing of IAPP and Aβ retards
the rate of IAPP assembly while enhances that of fibril formation by Aβ.38 Similarly, IAPP
has higher aggregation elongation rates than Aβ at the same concentrations and the mixture
has the corresponding values in between (Fig. 2-10B).
Based on a nucleated polymerization mechanism, the Wetzel group proposed an
aggregation kinetics analysis approach to determine the critical number of monomers, n*,
the conformational changes of which are rate-limiting for aggregation. 9,10 Briefly, during
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the initial growth phase before the rapid elongation, the increase of aggregation linearly
depends on the square of time, t2, and the slope is the power function of peptide
concentration with the exponent index corresponding to n*+2. Given the fast aggregation
of IAPP and IAPP-Aβ mixture and the resulting limited number of data points with high
noise-to-signal ratio for detailed analysis of the initial phases, we only apply the above
analysis to the aggregation of Aβ. We select data corresponding to the initial phase of Aβ
aggregation, and estimate the amount of aggregates based on the ThT fluorescence
intensity signal. For each concentration, we determine the slope with respect to t2 (e.g., Fig.
2-10C). Based on the log-log plot of the slopes vs. concentrations (Fig. 2-10D), we obtain
the exponent of ~3.5 and thus the value of n* ~1.5.
Many previous experiments have reported the observation of Aβ oligomers such as
pentamers and hexamers during the initial phase of amyloid aggregation. 73 Here, our
aggregation kinetics analysis reveals that the rate-limiting step of Aβ42 aggregation
requires the conformational changes of approximately 2 peptides, which can take place
within the initially formed Aβ oligomers. Based on our simulation results, these ratelimiting conformational changes correspond to the unfolding of α-helix in Aβ16-22. The
relatively slow aggregation of Aβ42 observed in vitro might result from the stabilization
of the helical conformation in Aβ16-22 in the self-associated oligomers such as
homodimers (Fig. 2-4). Upon binding with IAPP in the mixture, the strong inter-peptide
interactions shift the conformational equilibrium of Aβ16-22 from helical to the extended
conformation (Fig. 2-8), which in turn reduce the aggregation free energy barrier as in the
isolated Aβ peptides and thus shorten the aggregation lag time (Fig. 2-10).
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Conclusion
Combining all-atom DMD simulations with the complementary ThT assay, we
investigate the molecular mechanism for the accelerated co-aggregation of IAPP and Aβ42
mixture compared to the self-aggregation of Aβ alone. Our simulation results suggest that
the formation of IAPP-Aβ heterodimer is the first step towards their co-aggregation due to
electrostatic attraction between the two peptides with opposite net charges. The
computationally determined residue-wise inter-peptide interactions between IAPP and Aβ
in the heterodimer agree very well with previous experimental results of the hotspot regions
for their cross-association. Detailed analysis of our serial simulations at constant
temperature and replica exchange simulations at multiple temperatures reveal that the
strong inter-peptide interactions in the heterodimer introduce the unfolding of helix in the
amyloidogenic region of Aβ16-22, which makes Aβ ready for aggregation. The helix of
Aβ16-22 is otherwise stabilized in the homodimer of Aβ42, consistent with the
experimentally observed accumulation of helical contents before the rapid conversion into
β-rich aggregates.65,66
Our ThT experiments confirm previous experimental reports that the lag phase of
IAPP and Aβ co-aggregation is shorter than that of Aβ alone but only slightly longer than
IAPP. The kinetics analysis based on the nucleated growth polymerization theory indicates
that the critical number of peptides, whose conformational change is the rate-limit step for
aggregation, is approximately 2. With experimental observations of various Aβ42
oligomers and the in-registered β-sheet structures of Aβ16-22 in the core of Aβ42 amyloid
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fibrils, our combined computational and experimental studies suggest that the nucleation
of fibrillization corresponds to the helix unfolding of central hydrophobic cores (i.e., 1622) of approximately two peptides in these oligomers and the subsequent formation of
inter-peptide β-sheets in this region.67 Therefore, the binding of IAPP with Aβ in the
mixture reduces the free energy barrier for Aβ aggregation - i.e., the helix unfolding of the
central hydrophobic core of Aβ16-22, and thus promotes the co-aggregation with reduced
lag time for aggregation nucleation. With experimental evidences of IAPP being able to
cross the blood-brain barrier, the overproduction of IAPP in T2D, known as the
hyperamylinemia, may result into increased IAPP concentration in the brain, which in turn
promotes the formation of toxic aggregates with Aβ42 and increases the risk of AD. 34

Materials and Methods
DMD simulations. DMD is a special flavor of MD algorithm with high computational
efficiency and predictive power, which has been extensively used by our group and others
to study protein folding, protein dynamics, and amyloid aggregation. 74–76 In DMD, discrete
step functions instead of continuous potentials are used to model inter-atomic interactions.
The step-function potentials are adapted from the continuous Medusa force field to model
inter-atomic interactions.77 The non-bonded inter-atomic interactions include van der
Waals (VDW), solvation, hydrogen bond and electrostatic terms. The VDW parameters
were adopted from the CHARMM force filed and the EEF1 implicit solvent model is used
to model the solvation term.78,79 The hydrogen bond interactions are implicitly modeled
with a reaction-like approach.80 The Debye-Hückel approximation is applied to model the
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screened electrostatic interactions with the Debye length assigned ~10Å. We use the
Anderson’s thermostat to maintain the temperature, which is fixed at 300K except for the
replica exchange simulations. 81 To ensure sufficient sampling and avoid potential bias arise
from starting configurations, we perform multiple independent simulations for each
molecular system with different initial conditions, including randomized velocities,
intermolecular distances and orientations.

Simulation setup. In all simulations, we use the IAPP (PDB ID: 2L86) and Aβ42 (PDB ID:
1Z0Q) structures obtained from PDB to construct our systems. Counter ions Cl- and Na+
are also introduced into systems to achieve a neutral charge condition if necessary. For
both IAPP and Aβ peptides, we maintain the peptide concentration same as that of a single
peptide in a cubic box with the dimension of 83Å in all simulations. The periodic boundary
condition is used. In replica exchange simulations for IAPP and Aβ monomers, five
replicas are running at 275, 295, 315, 335, and 355K respectively, while eight replicas
running at 275, 290, 300, 310, 320, 330, 340, and 355K are performed to model the
heterodimer. The temperatures are chosen to ensure that the simulation exchange rates are
between 30% to 70%. During the analysis of simulation trajectories, we use the DSSP
program to compute protein secondary structures, and the weighted histogram analysis
method (WHAM) to evaluate the temperature dependence of thermodynamic
quantities.71,82
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Folding/Unfolding analysis. For the characterization of helix unfolding and refolding, we
based on two criterions: a helical to non-helical state conversion is considered if a structure
contains at least five helical residues inside amyloidogenic region converts into one
contains no more than two helical residues, and the conversion would be determined as
valid and recorded only if the new state could last for no less than 0.5ns simulation time.
Non-helical to helical state conversion is identified in a similar way. Structural percentage
and the number of conformational change are recorded according to all simulation
trajectories.

Calculation of the potential mean force (PMF). The two-dimensional PMF (or effective
free energy) is computed according to
PMF = –KBT ln P(Nhelical, Dend-to-end),

(2-1)

where KB is the Boltzmann constant, T corresponds to the simulation temperature 300K,
and P(Nhelical, Dend-to-end) is the probability of finding a Aβ16-22 segment containing Nhelical
helical residues, with an end-to-end distance of Dend-to-end at the time.

Thioflavin-T Fluorescence Assay. To study the kinetics of IAPP and Aβ42 amyloid fibrils
formation in vitro, our collaborators apply the ThT assay and single compound samples or
1:1 mixtures of concentrations from 1 to 5μM have been tested. All kinetic measurements
are performed at least in triplicate. The fluorescent ThT data are fitted to an empirical
equation to reproduce the change of fluorescent intensity ThT upon binding to the amyloid
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fibrils (Imax-I0), the apparent rate constant for fibrillization (k), and the lag time (tlag=t0-2/k)
to represent the time of nucleation before detectable amyloid formation:
𝐼

−𝐼

0
𝐼(𝑡) = 𝐼0 + 1+𝑒𝑚𝑎𝑥
−(𝑡−𝑡0)𝑘,

(2-2)

where I, I0 and Imax are the reading, initial and maximum fluorescence values, t0 is the time
required to reach half change of intensity.

Nucleation Kinetics. The details describing the nucleated growth polymerization
mechanism could be found elsewhere. 9,10 The important kinetics feature of the initial phase
of aggregation we examined here is the linear dependence of the aggregation content on
the time square (t2), and the power-law dependence of the corresponding slope on the
peptide concentration. The exponent index corresponds to n*+2, where n* is the critical
number of peptides whose conformational changes are the rate-limiting step for
aggregation nucleation. By fitting the ThT assay data with the sigmoidal equation (Eq. 22), we choose the initial phase with t<tlag and estimate the amount of aggregation by
normalizing them based on concentration conditions, ρ(I-I0)/Imax, with ρ corresponding to
the total peptide concentration.
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CHAPTER THREE
Zinc-coordination and C-peptide Complexation: A Potential Mechanism for the
Endogenous Inhibition of IAPP Aggregation

Introduction
The observation that IAPPs are stored inside β-cell granules at mM concentrations
for hours without apparent aggregation in healthy individuals suggests a mechanism of
endogenous inhibition of IAPP aggregation from the physiological environment inside βcell granules. Previous studies offer a comprehensive molecular insight into the
intermolecular binding between insulin and IAPP and uncover the corresponding inhibition
mechanism of IAPP aggregation. 52–54 However, since IAPPs are found almost exclusively
in the soluble halo fraction of β-cell granules while insulin is mostly insoluble in the core,
the insulin-IAPP interaction is limited and therefore a balance of Zn2+ and C-peptide colocalized with IAPP appears crucial for maintaining the native state of IAPP. 48 It has been
explored that Zn2+ has a concentration-dependent effect on IAPP aggregation, while Cpeptide is found to promote IAPP aggregation in vitro.47–49 Hence, we postulate that the
cooperative effect of Zn2+ and C-peptide rather than individual molecules may be
responsible for the endogenous inhibition of IAPP aggregation. In this study, we apply
DMD simulations to examine the effects of C-peptide and its coordination with Zn 2+ on
IAPP aggregation. The 31-residue C-peptide contains five acidic amino acids, which
contribute to Zn2+ coordination of the peptide at a 1:1 stoichiometry. 55,83 Our DMD
simulations show that a Zn2+ coordinated heterotrimer with two IAPPs and one C-peptide
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forms a well-defined stable molecular complex, which stabilizes IAPP in an aggregationincompetent helical conformation to inhibit the formation of β-rich aggregates. Further
ThT fluorescence assay and high-resolution transmission electron microscopy (TEM)
imaging validate our computational predictions, and reveal the maximum inhibition of
IAPP aggregation occurs at ~2.7:1:1 IAPP/C-peptide/Zn2+ molar ratio in vitro. Together,
our study suggests that the Zn2+ coordinated IAPP and C-peptide complexation plays a
critical role in the endogenous inhibition of IAPP aggregation inside β-cell granules.

Results and Discussion
Effects of C-peptide on IAPP self-association. We first simulate the dimerization of IAPP
at 300K with and without the presence of C-peptide to evaluate the effect of C-peptide on
IAPP self-association. For both molecular systems, 100 independent simulations are
carried out with each lasted 50ns, and the IAPP concentration is maintained the same. Our
simulation results reveal the accelerated dimerization of IAPP with the presence of Cpeptide, which is in agreement with experimental observations (Fig. 3-1). By fitting the
trajectories of binding probability exponentially, we obtain the aggregation rates as 0.052
ns-1 for simulations with C-peptide and 0.029 ns-1 for simulations of IAPPs alone
respectively, while their saturations are comparable. Further examination shows that Cpeptide binding doesn’t affect the secondary and quaternary structures of the IAPP dimeric
aggregates (Fig. 3-2). In both systems, IAPP adopts an N-terminal -helix and a small strand region around residue H18, with the whole peptide mostly unstructured. The
residue-wise binding frequency maps for both systems also share similar patterns, where
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L12, F15, L16, and F23 are highly engaged in IAPP self-association. Taken together, our
simulations suggest C-peptide could accelerate IAPP aggregation but exert little influence
on the structure of IAPP dimeric aggregates. This effect likely originated from electrostatic
attractions, as the net charge of IAPP is +2e (K1 and R11) while it is -5e for C-peptide (E1,
E3, D4, E11, and E27). The long-range electrostatic attractions induce a high local
concentration of IAPP to trigger their aggregation, while those highly engaged residues in
IAPP self-association are neutral and available for IAPP binding.

The corporative effect of Zn2+ and C-peptide on IAPP aggregation. It has been
experimentally shown that Zn2+ binds C-peptide at a 1:1 stoichiometry, we therefore study
the corporative effect of Zn2+ and C-peptide on IAPP aggregation with various molar ratios.
We simulate Zn2+, C-peptide, and IAPP at a 1:1:1 ratio first, with 100 independent
simulations and each performed for 50ns. Through our simulations, we observe Zn2+ binds
C-peptide more rapidly than its binding with IAPP and eventually the formation of a
heterodimer (Fig. 3-3A). After 50ns of simulation, the binding probability of Zn2+ with Cpeptide approaches 1, while the binding of Zn2+ with IAPP is only observed in 40% of the
final structures. The differential binding kinetics is possibly due to different driving forces.
C-peptide has five charged acidic residues all contributing to Zn2+ binding with a longer
interaction range and larger binding cross section, while the zinc-binding H18 on IAPP is
neutral with a shorter interaction range and smaller binding cross section. Our analysis
reveals that Zn2+ binds preferentially to the three N-terminal acidic residues of C-peptide
due to their mutual proximity (Fig. 3-3B&C).
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Since the coordination valence of Zn2+ is up to six and Zn2+ in the heterodimer
obtained above is still solvent exposed (Fig. 3-4A), it’s possible for Zn2+ to coordinate
additional molecules. Given that Zn2+ binds C-peptide at 1:1 stoichiometry while each Zn2+
already coordinates with at least three N-terminal acidic residues of C-peptide in the
heterodimer, we anticipate further coordination of Zn2+ with additional IAPPs instead of
C-peptides to form higher-order complexes. We also perform DMD simulations with one
Zn2+, one C-peptide, and up to three IAPPs. With two IAPPs, the Zn2+ is already fully
buried, preventing further coordination with additional IAPPs (Fig. 3-4B). Therefore, our
simulations suggest that each Zn2+ and C-peptide pair could coordinate up to two IAPPs,
forming a heterodimer or a heterotrimer.
We find the heterotrimer has a significantly stronger energy gain upon
complexation than the heterodimer, suggesting a higher thermodynamic stability (Fig. 35A). Secondary structure contents information reveals that the N-terminal IAPP6–15 and
the amyloidogenic region IAPP21–30 adopt helical structures in both complexes, while the
heterotrimer is significantly more helical (Fig. 3-5B). Moreover, the structural ensemble of
the heterodimer is diverse with a high number of representative structures (e.g., the top ten
centroid structures with clustering analysis in Fig. 3-6), suggesting a high structure
flexibility. Contrarily, heterotrimer structures are well-defined (e.g., three lowest energy
representative structures from clustering analysis in Fig. 3-5C), where each IAPP features
two helixes and separated by the C-peptide. Since the formation of inter-peptide hydrogen
bonds especially between the amyloidogenic regions is important for amyloid fibrillization,
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the heterotrimer with stable helixes in the amyloidogenic region is likely aggregationincompetent.
The nucleation propensity of both heterodimer and heterotrimer are evaluated in
silico by testing whether the IAPPs in the complexes can form further inter-peptide
hydrogen bonds with an additional IAPP. For the heterodimer, the binding between its
IAPP and the incoming one is similar to that of two IAPP alone, with extensive contacts
and hydrogen bonds formed (Fig. 3-7A). In contrast, IAPPs in the heterotrimer may still
associate with the incoming IAPP via dynamic binding, but they don’t form many contacts
or inter-peptide hydrogen bonds (Fig. 3-7B). Together, our simulation results suggest that
the formation of zinc-coordinated hetero-complexes between IAPP and C-peptide,
especially the stable heterotrimer instead of the intermediate heterodimer, stabilizes IAPP
in a helical and aggregation-incompetent state, which may play an important role in the
endogenous inhibition of IAPP aggregation.

In vitro studies of the effect of Zn2+ and C-peptide on IAPP aggregation. To validate our
computational predictions, our collaborators apply multiple in vitro studies including ThT
fluorescence assay, TEM imaging, and CD spectroscopy to examine the effect of Zn2+ and
C-peptide on IAPP aggregation.
Using a ThT fluorescence kinetic assay, we observe that in the presence of Zn2+, Cpeptide, or both Zn2+ and C-peptide at 1:1 stoichiometry, IAPP fibrillization is increased
or comparable with the control of IAPP alone after 14h incubation, except for the molar
ratios of 2.7:1:1 of IAPP/C-peptide/Zn2+ where IAPP fibrillization has been markedly
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decreased and its lag phase increased compared to the IAPP control (Fig. 3-8A and Fig. 39). Specifically, the ThT fluorescence intensity is increased at IAPP/C-peptide/Zn2+ molar
ratios of 0.3:1:1 and 0.7:1:1, and comparable to that for IAPP alone at molar ratios of
1.3:1:1 and 5.3:1:1.
High-resolution transmission electron microscopy (TEM) imaging provides direct
visualization of IAPP fibrillization and morphology. Consistently with the ThT assay for
14h of incubation, TEM imaging reveals the formation of fibrils and aggregates at IAPP/Cpeptide/Zn2+ molar ratios of 0.3:1:1, 0.7:1:1, 1.3:1:1, and 5.3:1:1 (Fig. 3-10). In contrast,
we do not observe conventional fibrillar structures but the presence of small aggregates of
8.4±2.7nm in size at IAPP/C-peptide/Zn2+ molar ratios of 2.7:1:1 (10 magnification in
Fig. 3-8B). Statistical analysis indicates that these aggregates are much softer (λ~187 nm,
Fig. 3-8C) than those of the IAPP control (λ~2885nm), confirming their amorphous and
non-fibrillar characteristics. IAPP fibrillization is persistent for IAPP/C-peptide of all
tested molar ratios from 0.3:1 to 5.3:1 (Fig. 3-8B and Fig. 3-10), while fibril softening
occurs also for all conditions (Fig. 3-8C). In addition, 24h incubation of IAPP with Zn2+
either enhances or inhibits IAPP fibrillization according to TEM imaging (Fig. 3-8B and
Fig. 3-10M–Q), although 14h incubation with Zn2+ causes modest IAPP fibrillization
inhibition in the ThT assay (Fig. 3-8A). Here, the observed concentration-dependence for
Zn2+ on IAPP aggregation is consistent with our previous studies. The experimentally
observed 2.7:1 ratio with maximum aggregation inhibition is close to the predicted 2:1
molar ratio between IAPP and C-peptide in the aggregation-incompetent heterotrimer (Fig.
3-5 and Fig. 3-8).
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Circular dichroism (CD) spectroscopy is utilized to assess the effects of Zn2+/Cpeptide on the secondary structures of IAPP at different molar ratios (Fig. 3-11). The IAPP
control shows a significant increase of β-sheet content from 32% and 77% coupled with a
drastic decrease in random coil, indicating IAPP aggregation after 24h incubation. 24h
incubation of IAPP/C-peptide/Zn2+ at 0.7:1:1, 1.3:1:1, 2.0:1:1 and 2.7:1:1 ratios yield
significant reductions in the β-sheet content and overall increases in turns and random coils.
Specifically, IAPP/C-peptide/Zn2+ at the molar ratio of 2.7:1:1 exhibits a marked decrease
from 77% and 34% in β-sheets along with an increase of α-helix from 19% to 25% and
turns from 4% to 40%, displaying a non-fibrillar characteristics. Such contrasting
conformational changes of IAPP at different IAPP/C-peptide/Zn2+ molar ratios are
consistent with the ThT and TEM results. Most importantly, the increase of helical content
at the 2.7:1:1 molar ratio agrees with the simulation predicted formation of stable α-helix
in the IAPP amyloidogenic region upon zinc-coordinated C-peptide complexation. At
lower IAPP to Zn2+/C-peptide molecular ratios, the unstructured C-peptides in the solution
results in the reduced overall helical content and increased coil content (Fig. 3-11B).
Therefore, our complementary biophysical experiments offer compelling evidence for the
predicted IAPP stabilization via zinc-coordinated complexation with C-peptide.
We also perform a cell viability assay to assess the differential cytotoxicity of the
various molecular species to insulin-secreting NIT-1 mouse pancreatic β-cell line. After
24h incubation, the cells are exposed to DNA binding dyes Hoechst 33342 and propidium
iodide. Hoechst 33342 freely diffuses into cells with preserved membranes, staining DNA
blue. Propidium iodide is permeable to compromised cell membranes, staining DNA of
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dead cells red. Thus, viable cells are identified by their intact nuclei with blue fluorescence,
whereas cell death is quantified by blue-red fluorescence or by fragmented blue nuclei with
immunofluorescence and light microscopy. We find that the controls of C-peptide and Zn2+
induce little toxicity (＜0.7%＝ in NIT-1 cells after 24h of treatment, while the controls of
IAPP and IAPP/Zn2+ (2.7:1) cause significant cell death at 22.2±6.5% and 30.3±8.1%,
respectively (Fig. 3-12). The sample of IAPP/C-peptide (2.7:1) induce minor toxicity
(~1.8%). In contrast, IAPP/C-peptide/Zn2+ at 2.7:1:1 molar ratio elicits minimal
cytotoxicity of ~1.1±0.2%, indicating remarkable mitigation of IAPP toxicity through zinccoordinated IAPP/C-peptide complexation. These in vitro results vindicate in silico
prediction as well as ThT, TEM, and CD observations.

Conclusion
In summary, the zinc-coordinated heterotrimer with one C-peptide and two IAPPs
is both thermodynamically and structurally stable, further with the amyloidogenic region
of IAPP stabilized in helical structure and the complex is suggested as aggregationincompetent. IAPP/C-peptide/Zn2+ mixture at 2.7:1:1 molecular ratio significantly reduces
the cytotoxicity of IAPP. In light of the coexistence of high concentrations of zinc, Cpeptide, and IAPP inside β-cell granules, this study suggests that zinc-coordinated
complexation between IAPP and C-peptide may play an important role in the endogenous
inhibition of IAPP aggregation in addition to the reported low pH effect. With future in
vivo verifications and structural characterizations of the molecular complex, therapeutic
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approaches mimicking or promoting such zinc-coordinated molecular complexes may
prove potent for the mitigation of aggregation-induced β-cell death in T2D.

Materials and Methods
DMD simulations. We apply all atom DMD simulations to study the effects of C-peptide
and Zn2+ coordinated complexation on IAPP aggregation. Our simulations are performed
under the same protocol as that introduced in chapter two.

Modeling zinc-coordination. The bindings between zinc and residues H18 on IAPP, D and
E on C-peptide are modeled by a number of constraints with a series of square well
functions. The interaction parameters are obtained by statistical analysis of all available
structures containing Zn2+ in the protein databank (PDB). To capture the distance and
angular dependence of zinc coordination, we compute the interatomic distances between
zinc and all atoms in the associated chemical groups, including imidazole of histidine and
carboxyl of aspartic (Asp) and glutamic (Glu) acids. Since the adjacent carbons (i.e., the
CB atom in aspartic acid and the CG atom in glutamic acid) are coplanar to carboxyl groups,
we also include their distances to the coordinated zinc. Based on the histograms of
interatomic distances, we determine the lower bound and upper bound values to assign the
coordination interactions. More details can be find elsewhere. 84

Simulation setup. In all simulations, we use the IAPP (PDB ID: 2L86) and C-peptide (PDB
ID:1T0C) structures obtained from PDB. To maintain the same IAPP peptide concentration,
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cubic boxes with the dimension of 100Å, 126Å and 144Å are used to model 1, 2, and 3
IAPPs, respectively. For simulations to obtain the binding kinetics (such as modeling the
effect of C-peptide alone on IAPP aggregation, and the binding of zinc/C-peptide/IAPP at
1:1:1 molecular ratio) and the modeling of zinc-coordinated IAPP and C-peptide
complexation, 100 independent simulations with different initial conditions are performed
to acquire sufficient samplings. For the nucleation test, 10 independent simulations for each
representative molecular complex are performed in parallel. Counter ions including Cl- and
Na+ are added to neutralize the systems if necessary. In addition, no coordination
interaction has been assigned between Zn2+ and the histidine of incoming IAPP in the
nucleation tests for both the heterodimer and heterotrimer.

Clustering Analysis. For the structural ensembles of both the heterodimer and heterotrimer,
we perform the clustering analysis using a hierarchical clustering program, oc
(www.compbio.dundee.ac.uk/downloads/oc). The clustering analysis is based on the
calculation of root-mean-square-deviation (RMSD) between two structures. Given the two
IAPP are indistinguishable in the heterotrimer, we perform structural alignment twice by
alternating the index of the two IAPPs and use the small RMSD value for any two structures.
For the clustering of the heterodimer, we set the cutoff value as 6Å and all low energy
structures are grouped into 10 large clusters (shown in Fig. 3-6) and 256 small ones with
one or two structures. We use the centroid node of the top 10 largest clusters for the
nucleation test. Given the larger size of the heterotrimer, we find a cutoff of 8Å is able to
effectively distinguish different structures, ending with 7 clusters. Compared to the
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heterodimer, the heterotrimer has significantly smaller structural variations. To further
improve our structural sampling of the heterotrimer, we apply 7 replica exchange DMD
(RXDMD) simulations with each of the centroid structure as the starting configuration. In
all simulations, the coordination interactions are maintained. Based on simulation
trajectories from all replica runs, we select again the low energy states, with potential
energy one standard deviation bellow the lowest Gaussian-like peak in the histogram.
Similar clustering analysis results into only 3 clusters with similar over-all structural
features as in Fig. 3-5C.

Materials. Human IAPP and C-peptide are obtained as lyophilized powders from AnaSpec.
Zinc chloride and ThT kit are acquired from Sigma-Aldrich. Milli-Q water has been used
for all dilutions.

In vitro studies. To validate our computational predictions, our collaborators apply multiple
in vitro studies including ThT assay, high-resolution TEM imaging, CD spectroscopy and
cell viability assay. Details can be found elsewhere in our publication. 84
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CHAPTER FOUR
IAPP Amyloid Inhibition by Small Molecules

Introduction
Some naturally occurring small molecules such as curcumin, resveratrol, and
epigallocatechin-3-gallate (EGCG) have shown potency in directing the progression of Aβ,
α-synuclein, IAPP, prions, and cystatin amyloids towards disordered and amorphous
aggregates.85–96 Among the above small molecules, EGCG is unique due to its better water
solubility and a high capability of remodeling amyloid fibrils. 97 Previous studies reveal
EGCG inhibit IAPP amyloids and against IAPP-associated toxicity by trapping IAPP into
an early intermediate state prior to IAPP amyloid formation. 98 EGCG could also remodel
IAPP amyloid fibrils, but couldn’t fully resolubilize them back to monomers, suggesting
IAPP fibrillization and EGCG remodeling are irreversible processes.58 In this study, we
combine transmission electron microscopy (TEM), atomic force microscopy (AFM), and
DMD simulations to extract nanoscale information on IAPP inhibition by fresh,
autoxidized, or glutathione (GSH)-reduced EGCG. We systematically analyze the
persistence length, contour length, as well as the morphology of IAPP and IAPP-EGCG
products versus time, and also reveal the molecular details of EGCG interacting with
soluble IAPP using DMD simulations. The nanoscale information uncovered by this study
has filled a knowledge gap between the atomic- and cellular-level understanding of IAPP
amyloidogenesis and mitigation against T2D.
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Results and Discussion
Nanoscale IAPP interfacing with EGCG. Our collaborators apply multiple experimental
studies to investigate the interaction between IAPP with different EGCG species and also
the inhibition effect. TEM imaging is the first applied, and reveals IAPP fibrillization in
the presence of EGCG and its derivatives. The selection of 1, 6, and 24h of fibrillization is
intended to cover the nucleation, end of elongation, and saturation phases respectively (Fig.
4-1C-N). IAPP seeds and protofibrils (30–200nm) start to emerge after 1h for IAPP alone
and IAPP with fresh, oxidized, or GSH-reduced EGCG. In the presence of EGCG, the
protofibrils appear amorphous with multiple splitting branches, differing from the linear
contours of the IAPP control. After 6h, IAPP forms long fibrils with a broad contour length
distribution (160–17400nm, as shown in Fig. 4-2A). Whereas all EGCG species yield short
and ramified fibrils (Fig. 4-1G&J&M and Fig. 4-2B-D). Fibrillization inhibition is
achieved with fresh EGCG at 6h (65–330nm; Fig. 4-1G and Fig. 4-2B), whereas oxidized
EGCG renders longer fibrils (40–1125nm; Fig. 4-1J and Fig 4-2C). At 24h, IAPP length
distribution is further broadened (60–20600nm; Fig. 4-2A), and all samples display
polymorphisms of long fibrils alongside short, soft, and curvy fibrils/protofibrils,
suggesting the coexistence of amyloid and non-amyloid fibrils. Further analysis reveals
that long IAPP fibrils are 7.9±0.9nm in thickness, whereas short ones are 9.8±2.5nm in
thickness with more pronounced variations due to their amorphous nature (Fig. 4-1E, inset).
In addition, short fibrils re-emerge at 24h, departing from the log-normal distribution of
such aggregation processes and corroborating the possibility of multiple fibrillation rates
for IAPP (Fig. 4-2A, grey circle). No small fibrils are observed after one month.
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As a result, fresh, autoxidized, and GSH-reduced EGCG could inhibit IAPP
fibrillization up to 6h, while small fibrils can be observed at 24h for all three cases (Fig. 42B-D, grey circles). We also find fresh EGCG exerts stronger inhibition than oxidized
EGCG up to 6h. At 24h, both fresh and oxidized EGCG display similar length distributions,
which is likely due to the gradual oxidation of fresh EGCG. With GSH-reduced EGCG,
shorter and fewer IAPP fibrils are observed than with other EGCG species, which is
confirmed by a narrower length distribution of the contour length (Fig. 4-2D). Persistence
length (λ) analysis using FiberApp also reveals three distinct fibril species with reduced
EGCG, whereas the other samples display the formation of two different species—long
and rigid fibrils along with short and soft fibrils or amorphous aggregates (Fig. 4-2E).
Accordingly, after 24h in the presence of fresh, oxidized, or GSH-reduced EGCG species,
the β-sheet content of IAPP is reduced from 39.2% to 34.3%, 35.7%, and 32.9%,
respectively, while the unstructured content enhanced from 37.3%, as seen in the IAPP
control, to 49.7%, 47.3%, and 51.7%, respectively (Fig. 4-2F and Fig. 4-3).

Molecular details of IAPP interfacing EGCG. To further provide the molecular insight of
IAPP interfacing with EGCG, we perform all-atom DMD simulations of 1, 2, 4, 6, and 8
IAPP peptides in the presence of EGCG (ligand) at equimolar ratio, with IAPP
concentration maintained the same. In all systems we modelled, we observe the binding of
EGCG with IAPP, and all simulation components tend to form a single cluster (Fig. 4-4
and Fig. 4-5). Examinations of the final aggregates reveal amorphous structures, with
EGCG ligands forming small clusters and scattering inside (Fig. 4-4B). These results are
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consistent with our experimental observations of IAPP aggregates of amorphous
morphology in the presence of EGCG. Additionally, the observed structures of IAPPEGCG complexes are drastically different from the reported complexes formed by IAPP
with small molecules resveratrol or curcumin.93 For resveratrol and curcumin, the
hydrophobic ligands aggregate into a nano-sized core, while IAPP peptides are bound to
the surface by burying hydrophobic residues and leaving hydrophilic residues exposed,
which turns into a well-defined off-pathway oligomer that subsequently inhibits
fibrillization. For EGCG, the small ligand clusters appear to scatter inside the amorphous
aggregates, which may not have prevented the continuous growth of aggregates, but
interfered with the formation of an elongated fibril instead, and would result in the
formation of curly aggregates (Fig. 4-1 and Fig. 4-2). This difference likely originates from
the higher solubility of EGCG compared with that of resveratrol or curcumin.
Further analysis of the binding suggests residues R11, F15, H18, F23, and Y37 on
IAPP, all of which are aromatic residues, exerts significantly stronger binding effect with
EGCG than other residues (Fig. 4-4D). As a polyphenol small molecule, EGCG ligand
contains multiple benzene rings, its strong binding with aromatic residues indicates πstacking is the driving force of IAPP-EGCG interfaces. This finding is similar to that of
our study on the off-pathway nano-assemblies of IAPP with curcumin and resveratrol,
where aromatic F15, F23, and Y37 residues are the most actively engaged in binding with
small molecules.93 The strong binding of EGCG with R11 indicates the importance of
hydrogen bonding.
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Simulations of IAPP interfacing oxidized EGCG. We also model the oxidized EGCG after
Theasinensin A (ThA), a cross-linked EGCG dimer identified as a major product of EGCG
auto-oxidization (Fig. 4-1B).99 DMD simulations are performed for 2, 4, and 6 IAPP
peptides mixed with ThA at a 2:1 ratio to keep a similar mass ratio to the simulations of
EGCG with IAPP. Our simulations display ThA binds IAPP in a similar profile as EGCG,
and forms similar complexes (Fig. 4-6C). However, ThA binds IAPP at a slower rate than
EGCG-IAPP binding, which may due to the larger size and therefore slower diffusion rate
of ThA. Consequently, EGCG tends to bind IAPP first before the IAPP self-association,
while self-association of IAPP takes place before its binding with ThA (Fig. 4-4C, Fig. 45, and Fig. 4-6A). The slower binding of ThA with IAPP may have contributed to the
reduced capability of ThA in inhibiting IAPP aggregation, as observed experimentally.

Conclusion
In summary, our study reveals that EGCG, oxidized EGCG, and (GSH)-reduced
EGCG all appear effective at IAPP amyloid inhibition. Different from small molecules
resveratrol or curcumin which could direct the IAPP amyloid aggregation process into a
well-defined off-pathway oligomer that subsequently inhibits fibrillization, EGCG ligands
would form small clusters and scatter around IAPP and result in amorphous aggregates,
which may subsequently prevent the continuous growth of aggregates. Our analysis of
binding between EGCG and IAPP reveal that the comparable effects on IAPP fibrillization
inhibition by EGCG species are indicative of the significance of π-stacking, as hydrogen
bonding and hydrophobic interactions are altered while aromatic EGCG moieties are
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conserved across the three cases. In light of the importance of π-stacking in peptide
assembly and fibrillization inhibition and remodeling, exploiting this mode of interaction
by molecular design may hold the key to effective peptide aggregation intervention.

Materials and Methods
DMD simulations. We apply all atom DMD simulations to study the interfacings of EGCG
and oxidized EGCG with IAPP. Our simulations are performed under the same protocol as
that introduced in chapter two.

Simulation setup. In simulations of EGCG binding with soluble IAPP peptides, the initial
structure of the IAPP monomer is obtained from the Protein Data Bank (PDB ID: 2L86),
and we use the EGCG structure obtained from PubChem (CID: 65064). To keep the peptide
concentration fixed during simulations of EGCG binding with various numbers of soluble
IAPPs, we vary the size of a cubic simulation box with a dimension of 63.7Å for one IAPP
to 127.4Å for eight peptides. Ten independent simulations are carried out for each system
with different initial conditions, including randomized velocities, intermolecular distances
and orientations. In our data analysis, we use an inter-atomic distance cutoff of 5Å to define
an atomic contact.

Materials. Human IAPP is obtained as lyophilized powder from AnaSpec. EGCG (≥95%)
and L-glutathione (≥98%) are acquired from Sigma-Aldrich. IAPP is weighed using a
Cubis MSE balance (0.01mg resolution; Sartorius), dissolved in water to a concentration
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of 100μM, and used immediately for TEM sample preparations. EGCG stock solutions
(1mM) are prepared immediately or 24h prior to TEM sample preparation to obtain fresh
or oxidized EGCG, respectively. Fresh EGCG solutions are colorless up until 6h, while
oxidized EGCG solutions appears light yellow. Therefore, nominally fresh EGCG would
have been partially auto-oxidized after 6h. Reduced EGCG is obtained by mixing the
polyphenol with GSH (1mM stock) at a 1:1 molar ratio in water. All solutions are prepared
using degassed ultrapure Milli-Q water (18.2MΩ·cm; Millipore Corporation, USA).

In vitro studies. To investigate the interaction between IAPP with different EGCG species
and also the inhibition effect, our collaborators apply multiple in vitro studies including
ThT assay, high-resolution TEM imaging, CD spectroscopy and AFM assay. Details can
be found elsewhere in our publication.100
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CHAPTER FIVE
Star Polymers Reduce the IAPP Toxicity via Accelerated Amyloid Aggregation

Introduction
Aggregation inhibition with the use of small molecules as well as polymeric
nanoparticles (NPs) has been a major strategy against amyloid-mediated toxicity.90,101,102
Polymeric NPs have been explored as protein aggregation inhibitors utilizing their tunable
hydrophobicity as well as their capacity for initiating H-bonding.103–106 Curiously, previous
studies report the amyloidogenesis of melanocyte protein Pmel17 in the human system is
entirely nonpathogenic.107 The rapid fibrillization of Pmel17, which transits from
monomeric form to mature amyloid fibrils within 3s, is a cytoprotective mechanism
through reducing the half-life of the most toxic intermediate products (i.e., oligomers and
protofibrils) to favor the formation of less toxic or nontoxic mature amyloid fibrils. Later
studies also show this effect can be extended to other pathogenic amyloids.108 Therefore,
the concept of fibrillization promotion instead of inhibition, provides a biomimetic and
perhaps counterintuitive strategy in the mitigation of amyloid cytotoxicity. In this study,
we synthesize and demonstrate the use of star-shaped polymer poly(2-hydroxyethyl
acrylate) (PHEA) nanostructure as an anti-IAPP agent capable of cytoprotective rescue of
pancreatic β-cells through the promotion of amyloid aggregation. 109 PHEA stars are
synthesized

using

a

reversible

addition-fragmentation

chain-transfer

(RAFT)

polymerization methodology and are weakly negatively charged, each possessing a
hydrodynamic size of ~12nm and containing on average 12 arms. Through biophysical
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characterizations, we demonstrate a significant, positive correlation between the promotion
of amyloid aggregation induced by PHEA stars and the reduction in IAPP-mediated
cytotoxicity both in vitro and ex vivo. Additionally, we also identify a new amyloid
morphology through our work, named “stelliform amyloids”, which is formed by the coaggregation of IAPP and PHEA stars at a molar ratio of 5:1. Atomistic DMD simulations
further reveal the PHEA stars possess rigid rod-like arms which can serve as linear
scaffolds for IAPP binding and therefore accelerate the nucleation of β-sheet aggregates by
increased local peptide concentration. Each arm of the PHEA stars could nucleate the
fibrillization of IAPP resulting in the stelliform amyloid morphology. This study opens the
door to the design and application of a new class of agents against amyloid diseases.

Results and Discussion
Modulation of IAPP fibrillization by PHEA polymers. Our collaborators first apply ThT
fluorescence assay to provide a measurement of both the extent and kinetics of amyloid
fibrillization over time. The control IAPP is shown to fibrillate with a nucleation period of
~2h followed by an exponential period of ~12h before reaching saturation at 14h (Fig. 51A). Incubation of PHEA with IAPP at molar concentrations of 1:125, 1:25, and 1:5 have
a promotional effect on IAPP fibrillization, with the largest increase in ThT fluorescence
observed at 1:5. Following the trend of increasing fibrillization with increasing
concentration of PHEA, the energetically unfavorable nucleation period is also shown to
significantly decrease with increasing concentration of PHEA, falling from ~3.5h in the
IAPP control to less than 30min with the highest concentration of PHEA. The reduction in
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IAPP lag time is also demonstrated through CD spectroscopy, wherein the presence of
PHEA to IAPP at the 1:5 ratio notably promotes the amyloidogenic conversion of random
coil content to β–sheets (Fig. 5-1B and Fig. 5-2). Over 2.5h, the β-sheet conversion in IAPP
with PHEA at 1:5 ratio (25-34%) is 2.3× more rapid than that of IAPP alone (29-33%).
Concordantly, IAPP contains 25% higher β-sheet content at 24h in the presence of PHEA
(55%) compared to that of IAPP alone (44%). This shift in prototypical IAPP aggregation
kinetics, in addition to the promotion of fibrillization overall, presents a case for rapid local
sequestration of IAPP seeds by PHEA.

Stelliform amyloid formation by PHEA. TEM imaging complement ThT and CD
measurements for fibrillating IAPP, allowing further analysis of persistence and contour
length of amyloid fibrils generated after 24h in aqueous solution in the presence and
absence of PHEA. After 24h, IAPP amyloidogenesis reaches the saturation phase, and long,
semi-flexible fibrils can be observed by TEM with some shorter species still present (Fig.
5-3A). Once fibril elongation and 3D cross-linking occurred at>5 days of amyloidogenesis,
amyloids form in-solution hydrogels, and generally, shorter species are absent.110
“Stelliform amyloids” are observed when PHEA incubated with IAPP at a 1:5 molar ratio
(Fig. 5-3A). These amyloids are characterized by a central nucleation “core”, ranging from
smaller clusters of 50-150nm to micrometers in diameter. Fibrils of low persistence
(average of 891.9nm compared with that of 2885±60nm for the IAPP control) and contour
length (<1350nm) are additionally observed radiating out from the core, forming the full
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stelliform structure of ~0.5μm in diameter for smaller cores and micrometers in diameter
for larger cores with some macroscopic aggregates visible in solution (Fig. 5-3A).
With lower concentrations of PHEA, the fibrillization products generally trend
towards matching the structural morphology of IAPP alone (Fig. 5-3B). IAPP amyloid
fibrils with significantly reduced contour lengths are produced with increasing PHEA
concentration, indicating polyphenol-like stabilization of growing fibrils through Hbonding; hydrophobic and π-π interactions by PHEA may have terminated fibril elongation,
resulting in a fibril population with predominantly low contour lengths.93 As fibril
elongation is mediated by amyloid seeds, the extensive exponential periods observed in the
ThT assay could be indicative of the PHEA-IAPP complex rapidly sequestering amyloid
seeds to render large populations of shorter fibrils, thus depleting the available seeding
population to perform elongation (Fig. 5-1).

Stelliform IAPP amyloids are cytoprotective in vitro and ex vivo. IAPP-mediated
cytotoxicity is assessed in an insulin-producing pancreatic β-cell line over a 24h period and
ex vivo in mouse islets after 48h (Fig. 5-4). PHEA stars are completely biocompatible at
all concentrations tested. In vitro, IAPP alone typically begin to induce cytotoxicity at ~6h
post-treatment with cell death progressing exponentially up until the 20-24h mark to an
end point toxicity value of 38%. When incubated with IAPP at 1:25 and 1:125 ratios, PHEA
stars delay the progression of IAPP toxicity by ~2h and reduce IAPP-mediated toxicity
overall compared to that of the IAPP control. However, when PHEA incubated with IAPP
at 1:5 ratio, cells are 94% viable after 24h, and low levels of cytotoxicity are only observed
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more than 15h post incubation. The cytoprotective capacity of PHEA stars at a 1:5 ratio to
IAPP is also seen ex vivo, where mouse islets treated with IAPP in the presence of the
highest concentration of PHEA stars (~8% relative cell death) demonstrate a significant
reduction in toxicity compared to that of IAPP alone (64%) after 48h treatment.
The near-complete mitigation in IAPP-mediated toxicity observed both in vitro and
ex vivo when IAPP is incubated with PHEA stars correlates with the stelliform amyloid
formation as observed (Fig. 5-3A). Likely the key to the cytoprotective nature of stelliform
amyloids lies first in their mechanism of formation and additionally in terms of the
structure itself. First, oligomeric and proto-fibrillar species formed as intermediates during
IAPP amyloidogenesis are widely considered responsible for the majority of IAPPmediated cytotoxicity, with far less toxicity attributed from amyloid fibrils. Concordantly,
rapid sequestering of toxic low-order IAPP species through the formation of stelliform
amyloids mediated by PHEA stars would reduce the local population of toxic species.
Lastly, it has also been purported that the cytotoxicity of amyloid fibrils is mediated
through partitioning of the hydrophobic, stiff fibrils into the cell membrane, leading to
disruption of the membrane and production of radical oxygen species.111–113 The structure
of stelliform amyloids, with a compact core and vastly reduced persistence and contour
lengths of radiating fibrils, would be unable to effectively partition into the lipid bilayer and
would also readily form a protein corona within the extracellular milieu through
electrostatic and hydrophobic interactions, further limiting any amyloid contact with
cellular membranes.114–116 Importantly, we observe complete protection from IAPPinduced cell death in primary mouse islets treated with PHEA stars at a 1:5 molar ratio.
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In silico study of the PHEA polymers and their effects on IAPP aggregation. To
complement the experimental findings, we examine the structural properties of model
PHEA polymers by all-atom DMD simulation. We first study the 2-arm PHEA polymers
with different degrees of polymerization (DP) and compute their corresponding radius of
gyration (Rg) values (Fig. 5-5A&D). The data reveal an approximately linear dependence
of Rg on DP (up to ~40), suggesting the PHEA stars are rather rigid (Fig. 5-5D). The
autocorrelation analysis of the polymer dynamics results in an estimated Kuhn length of
~36 repeats, which confirms the rigidity of the PHEA stars (Fig. 5-5E). To evaluate the
structure and dynamics of PHEA stars, we study an 8-arm PHEA model with molecular
compositions resembling the experimental data in all-atom DMD simulations. A rapid
equilibration in terms of Rg and ellipticity is observed (Fig. 5-5F). The average Rg of the
8-arm polymer is ~4.5nm, consistent with the experimentally measured hydrodynamic
radii ~4.9nm, and the high ellipticity value (close to 1) suggests the 8-arm PHEA adopt a
non-spherical conformation. Because of the high rigidity, the interactions between different
arms are found minimal beyond the covalent cross-links. Therefore, the all-atom DMD
simulations reveal a unique morphology of the PHEA that features a micellar structure with
a porous interior for encapsulating small molecules and IAPP peptides.
To provide molecular insight into IAPP-PHEA binding and its effect on IAPP selfassociation, we perform DMD simulations on two sets of molecular systems with one
containing six IAPP peptides along with a 6-arm PHEA polymer and another of six
peptides alone as the control (Fig. 5-5B). By monitoring the size of the largest IAPP
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aggregates, we find the presence of PHEA promotes the IAPP self-aggregation in silico
(Fig. 5-6A). On the basis of the last 25ns of simulations where the largest IAPP aggregates
are formed, the binding probabilities of each IAPP residue with PHEA reveal that both
polar and nonpolar residues could bind PHEA, though hydrophobic and aromatic residues
show a slightly higher binding propensity (Fig. 5-6B). As a result, the generally nonspecific
attractions between IAPP and PHEA lead to the accumulation of peptides on PHEA arms,
and the increased local peptide concentration accelerates the aggregation of IAPP
consistently with a previous coarse-grained computational study.117 We also examine the
secondary structure of IAPPs and their binding with PHEA along the simulation
trajectories, where a general trend of correlation between IAPP-PHEA binding and β-sheet
formation in IAPP aggregates is evident (Fig. 5-7). Comparison-average secondary
structure contents of the last 25ns between simulations with and without PHEA suggest the
PHEA binding accelerates IAPP self-association without significantly change in the
structure of the aggregates (Fig. 5-6C&D).
Next, we analyze the kinetics of β-sheet formation for simulations of IAPPs with
and without PHEA. We fit our data following the sigmoidal-like kinetics and obtain the
lag time and elongation rate for each independent simulation. Our data reveal the presence
of PHEA significantly reduces the aggregation lag time and broadens the distribution of
elongation rate, further suggest PHEA binding accelerates the nucleation of β-sheet
aggregates and induces heterogeneity in β-sheet elongation (Fig. 5-8B&C). Additionally,
wo compute the potential of mean force (PMF) with respect to the size of IAPP oligomers,
noligomer, and the degree of IAPP fibrillization, Qfibrillization. Two major basins can be
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observed in the PMF with or without presence of PHEA, corresponding to the IAPP
monomers/oligomers with little amount of β-sheet contents, and IAPP aggregates with high
amount of β-sheet contents, respectively (Fig. 5-9). Saddles connecting the two basins are
corresponding to the aggregation pathways and intermediates. According to our PMFs, the
presence of PHEA renders the non-β-sheet basin shallower and the saddle broader,
suggesting more pathways towards the final β-rich aggregates and is accounted for the
reduced aggregation lag time and heterogeneity in β-sheet elongation rate.

Conclusion
Inspired by the mechanism of Pmel17 amyloidogenesis, we have developed and
established that a polymeric star nanoparticle, PHEA, is capable of mitigating IAPPmediated toxicity both in vitro and ex vivo through PHEA-mediated promotion of IAPP
aggregation and formation of a unique “stelliform amyloid” morphology. PHEA stars
possess the structural properties of high rigidity, long arm length, and rich aromatic
moieties, and facilitate rapid deposition and fibrillization of IAPP monomers into amyloid
fibrils. Subsequently, this amyloid structure elicits significantly reduced toxicity in a
pancreatic β-cell line and in mouse islets when compared to the long, semi-flexible fibrils
typically formed by IAPP. Our study suggests that the shape/morphology of the PHEA
stars is likely a contributing factor in the IAPP-PHEA interaction, and shortening of the
oligomer lifetime through amyloid aggregation promotion represents a potential strategy
to be explored within the larger context of amyloid research. This study has shed new light
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on the IAPP structure-toxicity relationship and presents an alternative blueprint for the
design of polymeric nanomedicines against amyloidogenesis.

Materials and Methods
DMD simulations. Our DMD simulations are performed under the same protocol as that
introduced in chapter two.

Simulation setup. All the PHEA model structures are constructed with the Avogadro
molecular builder software and energy minimized with the MMFF94s force field.
MedusaScore, an extension of the Medusa force field, is adapted to model the polymers in
addition to IAPP. The MedusaScore is parametrized on a large set of ligands and is
transferrable to different molecular systems. The predictive power of MedusaScore has
been validated in various benchmark studies, including recent community structureactivity resource (CSAR) blind ligand-receptor docking prediction exercises.43,119
For each 2-arm PHEA, we perform 20 independent simulations at 300K with
different starting configurations. Each independent simulation is lasted for 300ns, and an
accumulative 6μs simulation is obtained for the polymer model. We use the last half of all
simulations to compute the radius of gyration (Rg) values of the modeled polymers. For
the 8-arm PHEA, 20 independent simulations are performed at 300 K with different starting
configurations, each of which lasted 200ns.
The IAPP (PDB ID: 2L86) structure is obtained from PDB. Counter ions Cl1- are
introduced to achieve a neutral charge condition if necessary. For systems containing six
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IAPPs, the peptide concentration is maintained by fixing the dimension of the simulation
box as 120Å, and periodic boundary conditions are applied. For each of the multimolecular systems, 20 independent simulations starting with different intermolecular
distances and orientations are performed at 300K with each run lasted 100ns.
Secondary structure analyses are performed using the dictionary secondary
structure of protein (DSSP) method. For each snapshot structure, the secondary structure,
such as helix, sheet, coil, and turn, for each residue has been obtained. An empirical
sigmoidal function
𝑦=

(𝐼𝑚𝑎𝑥−𝐼𝑚𝑖𝑛)
(1+𝑒𝑥𝑝(−𝑘(𝑡−𝑡0 )))

+ 𝐼𝑚𝑖𝑛 ,

(5-1)

is adopted to fit the kinetics of the total number of residues in the β-sheet conformation,
where fitting parameters A, B, t0, and k correspond to the max and min values of
aggregation, the midpoint time of aggregation, and the elongation rate, respectively. The
lag time is determined as
𝑡𝑙𝑎𝑔 = 𝑡0 − 2/𝑘,

(5-2)

In the potential of mean force (PMF) calculation, normalized sigmoidal function,
Qfibrillization=1/(1+ exp(−k(t − t0))), is used to quantify the extent of fibrillization for each
independent simulation. For a given snapshot, the distribution of IAPP oligomers is
analyzed, where any two peptides interconnected by at least one intermolecular heavy atom
contact (the cutoff of 0.55nm) is defined to belong to an oligomer. The size of an oligomer,
noligomer, was defined by the number of IAPP peptides forming the aggregate. The twodimensional PMF (or effective free energy) is computed according to
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PMF = –KBT ln P(noligomer, Qfibrillization),

(5-3)

where KB is the Boltzmann constant, T corresponds to the simulation temperature 300K,
and P(noligomer, Qfibrillization) is the probability of finding a peptide in an oligomer with the
size of noligomer and the extent of fibrillization Qfibrillization at the time.

Materials. 2-Hydroxyethyl acrylate (HEA) is purchased from Sigma-Aldrich and
deinhibited by passing through a column of basic alumina. S,S′-Dibenzyl trithiocarbonate
(DBTC), N,N′ methylenebis- (acrylamide) (X) is purchased from Sigma-Aldrich. Azobis(isobutyronitrile) (AIBN) is purified by recrystallization from methanol before use.
Dimethyl sulfoxide (DMSO) is purchased from Merck Millipore and used as received.
Human IAPP is obtained in lyophilized powder form from AnaSpec and made up to a
200μM stock immediately prior to an experiment or allowed to fibrillate at 25°C for >5
days to produce mature IAPP amyloids. All materials are weighed out on a Cubis MSE
balance (Sartorius, 0.01mg resolution) and made up fresh in Milli-Q water prior to
experiments unless otherwise specified. Thioflavin-T (ThT) dye (Sigma-Aldrich) is
prepared fresh for each experiment at a 250μM stock solution. Propidium iodide (PI) dye
stock solution (1mg/mL in water) is stored at -20°C. Detailed information about raft
synthesis of poly(2-hydroxyethyl acrylate) stars can be found elsewhere. 118

In vitro and ex vivo studies. The experimental studies carried out by our collaborators can
be found in our publication.
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FIGURE CAPTIONS

Figure 2-1. Time evolution of atomic contacts between IAPPs (green), Aβs (blue), and
IAPP-Aβ (orange). Data are derived from simulation system containing two IAPPs and
Aβs. Error bars denote the standard error of means (SEM).
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Figure 2-2. Time evolution of peptide cluster species for IAPP-Aβ mixtures with
molecular ratios of (A) 2:2 and (B) 4:4. The number of each species weighted by the
number of peptides forming the cluster is averaged over the number of independent
simulations. For simulations with 2:2 ratio, all possible cluster species are shown. In the
case of 4:4 ratio, only the six most-populated cluster species are shown.

51

Figure 2-3. Identification of hot regions for inter-peptide interactions in both cross- and
self-associations of IAPP and Aβ. Residue-wise contact frequency maps are computed for
(A) IAPP and Aβ binding in heterodimer simulations, and self-association of (B) Aβ and
(C) IAPP in dimer simulations. Histograms are also obtained to show the total contact
frequency of each residue. (D) Sequence fragments with the highest degree of similarity
between Aβ and IAPP are highlighted in orange and blue, while the domains
experimentally-identified to be important for both their cross- and self-associations are
highlighted in gray.
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Figure 2-4. The secondary structure propensity of Aβ and IAPP in monomer, heterodimer,
and homodimer. (A, C) Helix propensity and (B, D) β-sheet propensity of each peptide
residue, where data for different peptide states are shown in black, red and blue respectively.
All data are averaged over the last half of 20 independent simulations, with each performed
for 600ns simulation time. Error bars denote the standard error of means (SEM).
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Figure 2-5. The secondary structure propensity of Aβ and IAPP in monomer, heterodimer,
and homodimer. (A, C) Random coil propensity and (B, D) turn propensity of each peptide
residue, where data for different peptide states are shown in black, red and blue respectively.
All data are averaged over the last half of 20 independent simulations, with each performed
for 600ns simulation time. Error bars denote the standard error of means (SEM).
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Figure 2-6. Conformational dynamics of the helix unfolding and refolding in the
amyloidogenic region of Aβ16-22. Numbers of transition between helical and non-helical
state are recorded for (A) Aβ monomer simulations and (B) IAPP-Aβ heterodimer
simulations. IAPP peptides are colored in green and Aβ in cyan, while the amyloidogenic
region of Aβ16-22 is highlighted in red. Observation of the helix unfolding/refolding
events and structural percentage of the helical/non-helical state are determined over 20
independent simulations, with each lasted 600ns. Simulation snapshots are used to display
peptide structures.
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Figure 2-7. Replica exchange simulations of IAPP monomer, Aβ monomer, and
heterodimer. The temperature dependence of (A) heat capacity (𝐶𝑉 ), (B) number of atomic
contacts between IAPP and Aβ in heterodimer, (C) secondary structure contents of Aβ in
monomer/heterodimer,

and

(D)

secondary

monomer/heterodimer are displayed respectively.
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Figure 2-8. The conformational free energy landscape of the amyloidogenic Aβ16-22 at
300K in simulations of (A) the Aβ42 monomer and (B) the Aβ42-IAPP heterodimer. Using
the WHAM analysis of the replica exchange simulation trajectories, the 2D PMF is
computed as the function of the number of helical residue and end-to-end distance. The
basins correspond to helical (a, α), partially helical intermediate (b, β), and non-helical (c,
d and γ, δ) states. IAPP peptides are shown in green and Aβ in cyan. The amyloidogenic
region of Aβ16-22 is highlighted in red.
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Figure 2-9. ThT fluorescence intensity of peptides at (A) 3.0μM, (B) 4.0μM, and (C)
5.0μM indicating the sigmoidal aggregation kinetics. Peptide concentration of 1.0, 2.0, 2.5,
3.0, 3.5, 4.0, and 5.0μM are examined with multiple repeats, with their fluorescence
intensity normalized into 0~1. Data from 9 individual tests are shown in this figure.
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Figure 2-10. In vitro studies of IAPP-Aβ cross- and self-association. The concentration
dependence of (A) the aggregation lag time and (B) fibril elongation rate for Aβ-IAPP coaggregation (blue), and the self-aggregation of Aβ (black) and IAPP (red). (C) For the
aggregation of Aβ, the amount of aggregates during the initial phase of aggregation linearly
depends on the square of time, t2. (D) The log-log plot of the slops in panel C vs. the peptide
concentrations shows the power-law dependence. The linear fit in the log-log plot results
into an exponent index of ~3.54s.
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Figure 3-1. DMD simulations of IAPP dimerization with and without the presence of Cpeptide. (A) Trajectories of binding probability and (B) trajectories of number of atomic
contacts between different peptides. Error bars denote the standard error of means (SEM).
Structural snapshots are displayed for simulation of (C) IAPPs alone and (D) IAPPs with
C-peptide. IAPP peptides are colored in cyan while C-peptide in magenta.
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Figure 3-2. Secondary structure information and residue-wise binding frequency maps of
IAPPs with and without C-peptide. (A, B) Secondary structure content probability of each
residue in IAPP. Data are derived from the last 25ns of simulations and averaged over 100
independent trajectories. (C, D) Contour plots illustrating the residue-wise binding
frequency for IAPP-IAPP association. Data are derived from the full-time simulations and
averaged.
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Figure 3-3. DMD simulations of the binding between Zn2+, C-peptide, and IAPP at 1:1:1
molar ratio. (A) Trajectories of binding probabilities of Zn2+ with C-peptide and Zn2+ with
IAPP. Error bars denote the standard error of means (SEM). (B) Trajectories of the
averaged binding probabilities of Zn2+ with five acidic residues on C-peptide and Zn2+ with
H18 on IAPP respectively. (C) Structural snapshots illustrating Zn2+ coordinating Cpeptide and IAPP. IAPP are colored in cyan and C-peptide in magenta, while the zinc ion
is illustrated as a grey sphere. Zn2+-binding residues on both peptides are highlighted as
sticks.
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Figure 3-4. Surface structures of the Zn2+ coordinated heterodimer and heterotrimer of
IAPP and C-peptide. (A) The zinc ion inside the heterodimer is partially solvent exposed,
and can possibly bind additional incoming IAPP. (B) The zinc ion inside the heterotrimer
is fully buried, preventing further coordination with IAPP. In both panels, IAPPs (and
surfaces) are colored in cyan, C-peptide (and surfaces) are colored in magenta. Zinc ions
are showed as a grey sphere. All binding residues (and surfaces) are highlighted in
enlargements, with stick illustrations and colored in white.
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Figure 3-5. DMD simulations of the heterodimer and heterotrimer. (A) The energy gains
upon complexation. (B) Secondary structure contents information of IAPP in the
heterodimer and heterotrimer respectively. (C) Representative structures of a heterotrimer.
IAPP is colored in cyan while C-peptide in magenta. Zinc-binding residues are highlighted
as sticks.
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Figure 3-6. The centroid heterodimer structures of the top 10 clusters, with corresponding
percentage of 1.57%, 2.36%, 1.57%, 1.57%, 1.77%, 3.74%, 2.16%, 1.97%, 2.56% and 1.18%
of total structural ensemble respectively. IAPPs are colored in cyan while C-peptide
colored in magenta, and zinc ion shown as a grey sphere. All binding residues (and surfaces)
are highlighted as sticks and colored in white.
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Figure 3-7. Nucleation test of zinc-coordinated heterodimer and heterotrimer. (A) The
binding of IAPP in the heterodimer with an incoming IAPP are estimated in terms of IAPPIAPP binding probability, number of atomic contact, and inter-chain hydrogen bond. The
dimer simulations of two IAPPs alone is denoted as A-A binding and colored in grey, while
IAPP in the heterodimer is denoted as A1 and the incoming IAPP as A2 respectively. (B)
IAPPs in the heterotrimer are denoted as A1 and A2, while the incoming IAPP id denoted
as A3. Data are averaged over both IAPPs in the heterotrimer.
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Figure 3-8. Experimental studies of zinc-coordinated IAPP-C-peptide complexation. (A)
ThT fluorescence assay for 14h of sample incubation. The time dependent data are shown
in Fig. 3-9. (B) TEM imaging of IAPP aggregation after 24h incubation with zinc and/or
C-peptide. Only the samples with molecular ratio of 2.7:1 are shown while the rest is in
Fig. 3-10. (C–F) Statistical analysis of the persistence length and contour length of IAPP
fibrils. The concentration of IAPP is kept 16.9mM in all samples.
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Figure 3-9. ThT fluorescence assay data on zinc-coordinated complexation for 14h of
sample incubation. (A) ThT fluorescence assay of IAPP with C-peptide and zinc of various
molar ratios. (B) ThT fluorescence assay of IAPP with C-peptide of various molar ratios.
(C) ThT fluorescence assay of IAPP with zinc of various molar ratios. The final
concentration of IAPP is 16.9μM in all samples.
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Figure 3-10. High-resolution TEM imaging of zinc-coordinated complexation for 24h of
sample incubation. (A-E) IAPP with C-peptide and zinc of various molar ratios. (F)
Magnified view of an aggregate in D. (G-K) IAPP with C-peptide of various molar ratios.
(L) IAPP control. (M-Q) IAPP with zinc of various molar ratios. (R) C-peptide control.
The final concentration of IAPP is 16.9μM in all samples. Scale bars: 200nm unless
specified otherwise.
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Figure 3-11. CD measurement of the secondary structures of IAPP control and IAPP/Cpeptide/Zn2+ mixtures. (A) IAPP control of 25mM at 0h and 24h incubation (upper), and
IAPP/C-peptide/Zn2+ at different molar ratios after 24h incubation (lower). (B) Secondary
structural contents for the various molecular systems.
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Figure 3-12. C-Peptide protects β-cells from IAPP-induced cell death. NIT-1 cells are
untreated (control) or incubated with IAPP, C-peptide, Zn2+ or combination as indicated
for 24h. Cell death is evaluated by Hoechst-33342 (blue)/propidium iodide (red). White
arrows indicate propidium iodide positive cells. Data shown are means ± SEM of 4
independent experiments. *P ＜ 0.05.
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Figure 4-1. (A) Schematic definitions of l and λ of the fibril. λ is defined as the length over
which angular correlations in the tangent direction decrease by e times. Factor 2 in the
formula accounts for 2D Euclidean geometry. (B) ThT fluorescence assay of IAPP
fibrillation with presence of fresh EGCG, oxidized EGCG, or reduced EGCG. (C–N) TEM
images of IAPP fibrillization at 1, 6, and 24h of incubation time with or without EGCG
species. All chemicals are prepared at 50μM concentrations and mixed with a 1:1 molar
ratio. Scale bar: 100nm.
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Figure 4-2. Contour length of IAPP fibrils incubated for 0–24 h for (A) IAPP control and
(B–D) IAPP incubated with fresh, oxidized, or reduced EGCG. The dashed grey circles
indicate populations of small fibrils at 24 h. (E) IAPP fibril persistence length versus time
for the four sample conditions. (F) Secondary structures of IAPP incubated with fresh
EGCG, oxidized EGCG, or reduced EGCG after 24h of incubation, showing reduced βsheet and increased unstructured content compared with IAPP control. All chemicals are
prepared at 50μM concentrations and mixed with a 1:1 molar ratio where applicable.
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Figure 4-3. Circular dichroism (CD) spectra of IAPP at 0h and 24h, and IAPP with fresh
EGCG, oxidized EGCG and reduced EGCG after 24h of incubation (control spectra
subtracted).
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Figure 4-4. DMD simulations of 8 EGCG ligands binding with 8 IAPPs. (A) Structural
snapshot illustrating the aggregation process. IAPP are colored in cyan while EGCG are in
orange. (B) Final aggregates obtained from 4 independent simulations. (C) Trajectories of
the total number of atomic contacts between IAPP-IAPP (black), EGCG-IAPP (red), and
EGCG-EGCG (cyan). Data are averaged over 10 independent simulations. (D) Averaged
number of atomic contacts between EGCG and each residue on IAPP. Arrows indicate the
strong-binding residues.
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Figure 4-5. DMD simulations of various numbers of EGCGs and IAPPs: (A) 1:1, (B) 2:2,
(C) 4:4 and (D) 6:6. All data are averaged over 10 independent simulations for each
molecular system. From left to right within each panel displays the trajectories of potential
energy, the trajectories of total number of contacts among different simulation components,
and the number of atomic contacts between EGCG and each residue on IAPP, respectively.
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Figure 4-6. DMD simulations of IAPP aggregation with ThA. (A) Trajectories of the total
number of atomic contacts between IAPP-IAPP (black), ThA-IAPP (red), and ThA-ThA
(cyan). Data are averaged over 10 independent simulations. (B) Averaged number of
atomic contacts between ThA and each residue on IAPP. Strong-binding residues are
highlighted in red. (C) Structural snapshot illustrating the aggregation process. IAPP are
colored in cyan while ThA are in orange.
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Figure 5-1. (A) ThT fluorescence of IAPP in the presence of PHEA stars over 24h. Dotted
lines represent sigmoidal curve fitting (least-squares fit); error is SEM (n=2). (B)
Secondary structure transitions in IAPP mapped by circular dichroism at 0, 2.5, and 24h
time points. Lines are intended to guide the eye. The concentration of IAPP in all
experiments is 25μM.
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Figure 5-2. Normalized circular dichroism spectra of IAPP (25μM) alone and in the
presence of PHEA stars after incubation in Milli-Q water at 0, 2.5 and 24h.
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A

B

Figure 5-3. (A) TEM imaging of fibrillating IAPP in the presence and absence of PHEA
stars after 24h incubation. Stelliform amyloids are seen at PHEA with IAPP at 1:5 molar
ratio. Scale=100nm. (B) Structural analysis of amyloid fibrils visualized above. IAPP
concentration in all experiments is 25μM.
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Figure 5-4. Protective effect of PHEA stars against IAPP-mediated cytotoxicity in
pancreatic β-cells and islets. (A) In vitro cytotoxicity of fibrillating IAPP and mature IAPP
amyloids in the presence and absence of PHEA in βTC6 cells over 24h. Error=SEM (n=3).
(B) Ex vivo cytotoxicity of fibrillating IAPP and PHEA with IAPP at a 1:5 molar ratio in
mouse islets after 48h incubation. Flow cytometry data is representative of n=5
experiments summarized in the graph. Error=SEM. ****p < 0.0001, one-way ANOVA
with Tukey’s correction.
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Figure 5-5. Simulations of PHEA stars. (A-C) Chemical structures of the 2-arm, 6-arm,
and 8-arm PHEA modelled in simulations. (D) The radius of gyration (Rg) of 2-arm PHEA
increases approximately linearly with the degree of polymerization. (E) Autocorrelation
analysis of 2-arm PHEAs. The exponential fitting returns a persistence length of n~18 (i.e.,
corresponding to a Kuhn length of ~36). (F) Time evolution of Rg and ellipticity of an 8arm PHEA model with equilibrated structural snapshots in the inset (three different views).
Error bars denote the standard error of means (SEM).
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Figure 5-6. Binding of IAPP with 6-arm PHEA. (A) Time evolution of the size of the
largest IAPP aggregates in DMD simulations of 6 IAPPs with and w/o the presence of a 6arm PHEA. Error bars denote the standard error of means (SEM). (B) Binding probability
of each IAPP residue with PHEA. Residues with the highest binding probabilities are
highlighted in red. (C-D) β-sheet and α-helix content propensities of each IAPP residues.
Data are averaged over the last 25ns of DMD simulations.
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Figure 5-7. β-sheet formation in IAPP aggregates is correlated with their binding with
PHEA. Secondary structure change of IAPP peptides (C1 ~ C6) is shown in the upper panel,
while the PHEA-binding of each peptide is illustrated as red pixels in the bottom panel
accordingly. Snapshots at the 36ns and 79ns are used to display the structure of the modeled
system. It’s noticeable that one of the peptides (C5) is not clustered in the IAPP aggregate.
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Figure 5-8. Binding with PHEA star reduces the aggregation lag time and induces the
heterogeneity in the fibril elongation rate of IAPP self-association. (A) Time evolution of
the total number of IAPP residues in β-sheet content with and w/o the presence of a 6-arm
PHEA. (B-C) Distributions of the lag time and elongation rate of 20 independent
simulations.
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Figure 5-9. Aggregation free energy landscapes of IAPP without (A) and with (B) PHEA.
3D potentials of mean force (PMFs) with respect to IAPP oligomer size and degree of
fibrillization are used to derive the free energy landscapes in front and top views. Snapshot
structures with IAPP in cartoon and PHEA polymers in stick are shown to illustrate the
basins and saddles of the energy landscapes.
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